Trelegy Ellipta Approval History
- FDA approved: Yes (First approved September 18th, 2017)
- Brand name: Trelegy Ellipta
- Generic name: fluticasone furoate, umeclidinium and vilanterol
- Company: GlaxoSmithKline
- Treatment for: COPD
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is an inhaled corticosteroid, long-acting muscarinic antagonist (LAMA) and long-acting beta2-adrenergic agonist (LABA) combination for the treatment of patients with chronic obstructive pulmonary disease (COPD).
Development History and FDA Approval Process for Trelegy Ellipta
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.